Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 4/20 | 0.44 |
| ▸ | MLNR | O43193 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4972718 | 0.90 | SPPL2A (0.50) | SPPL2ACTSDMLNRABCB11LMNA | |
| SCHEMBL14189475 | 0.90 | SPPL2A (0.50) | SPPL2ACTSDMLNRABCB11LMNA | |
| SCHEMBL5928183 | 0.89 | CTSD (0.50) | SPPL2ACTSDMLNRABCB11LMNA | |
| SCHEMBL14189517 | 0.89 | SPPL2A (0.47) | SPPL2ACTSDMLNRABCB11LMNA | |
| SCHEMBL4973117 | 0.89 | SPPL2A (0.48) | SPPL2ACTSDMLNRABCB11LMNA | |
| SCHEMBL14189499 | 0.89 | SPPL2A (0.48) | SPPL2ACTSDMLNRABCB11LMNA | |
| SCHEMBL7518698 | 0.88 | SPPL2A (0.46) | SPPL2ACTSDMLNRABCB11LMNA | |
| SCHEMBL5914806 | 0.88 | SPPL2A (0.46) | SPPL2ACTSDMLNRABCB11LMNA | |
| SCHEMBL14189518 | 0.88 | SPPL2A (0.48) | SPPL2ACTSDMLNRABCB11LMNA | |
| SCHEMBL14614321 | 0.87 | SPPL2A (0.45) | SPPL2ACTSDMLNRABCB11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098202-B2 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20060189611-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20040260095-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2004-12-23 | — | — | US | disclosed |
| US-6730669-B2 | PROPHYLACTICALLY PREVENTING RETROVIRAL INFECTION OR THE SPREAD OF A RETROVIRUS, AND TREATMENT OF A RETROVIRAL INFECTION | G. D. SEARLE & CO. | 2004-05-04 | — | — | US | disclosed |
| US-20030216435-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. | 2003-11-20 | — | — | US | disclosed |
| EP-0813542-B1 | AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 2002-10-16 | — | — | EP | disclosed |
| US-6458785-B1 | AIDS THERAPY | G. D. SEARLE | 2002-10-01 | — | — | US | disclosed |
| US-20020111368-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | GETMAN DANIEL P (US) | 2002-08-15 | — | — | US | disclosed |
| US-6310080-B1 | TREATING RETROVIRAL INFECTIONS SUCH AS AIDS | G. D. SEARLE & CO. | 2001-10-30 | — | — | US | disclosed |
| US-6140505-A | REACTING A BENZO FUSED HETEROCYCLIC COMPOUND WITH AN SO3 COMPLEX IN THE PRESENCE OF A WATER IMMISCIBLE, NON-REACTIVE SOLVENT, AT A TEMPERATURE OF FROM ABOUT 0 TO ABOUT 75 DEGREES C., COOLING AND THEN ADDING OXALYL HALIDE. | G. D. SEARLE & CO. (US) | 2000-10-31 | — | — | US | disclosed |
| US-5968970-A | TREATMENT OF HIV | G. D. SEARLE & COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| US-5965601-A | NOVEL COMPOUNDS FOR INHIBITING REPLICATION OF A RETROVIRUS; TREATING HIV | G. D. SEARLE & CO. (US) | 1999-10-12 | — | — | US | disclosed |
| WO-1996028463-A1 | AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216435-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | SPPL2A 268/4885CTSD 61/4885MLNR 2955/4885 |
| US-20020111368-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | SPPL2A 268/4885CTSD 61/4885MLNR 2955/4885 |
| US-20040260095-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | SPPL2A 268/4885CTSD 61/4885MLNR 2955/4885 |
| US-20060189611-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | SPPL2A 268/4885CTSD 61/4885MLNR 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.